A point mutation in Phe71Ser in glycoprotein IX as a genetic cause of Bernard–Soulier syndrome: case report

Imtinan K. Alsahafi1, Ibrahim Al-Harbi2, Shahad M. Aldor1, Bilqis A. Albarakati1 & Ghaida B. Alahmadi1

1Faculty of Medicine, Umm Al-Qurra University, Mecca, Saudi Arabia
2Department of Pediatrics, Faculty of Medicine, Umm Al-Qurra University, Mecca, Saudi Arabia

Correspondence
Ibrahim Al-Harbi, MD, FRCPC, Division of Pediatric Hematology Oncology, Department of Pediatric, King Fahad Armed Forces Hospital, P. O Box 9862, Postal Code 21559, Jeddah, Saudi Arabia.
Tel: +966 55 560 9700;
E-mail: ialharbi@hotmail.com

Funding Information
No sources of funding were declared for this study.

Received: 22 August 2017; Revised: 31 December 2017; Accepted: 20 January 2018

Clinical Case Reports 2018; 6(4): 686–689
doi: 10.1002/ccr3.1427

Research Institution: Division of Pediatric Hematology Oncology, Department of Pediatric, King Fahad Armed Forces Hospital.

Introduction
Bernard–Soulier syndrome (BSS) is an inherited bleeding disorder transmitted in a rare autosomal recessive manner. It is caused by mutations of the genes encoding for the subunits of the glycoprotein (GP) Ib-IX-V complex. Normally, group of linked proteins called (GP) GPIBA (GPIb), GPIBB (GPIb), GP9 (GPIX), and GP5 (GPV) are found on the surface of the platelets that activated with vessels wall injury. (GP) Ib/IX/V complex acts as a platelet receptor and works as binding site for coagulation factors to help with platelet adhesion to the site of injury [1].

In patients with BSS, defect in the glycoproteins complex leads to an abnormal platelet adherence and increases bleeding tendency [2].

The frequency of BSS based on case reports from Europe, North America, and Japan has been estimated to be one in one million [2]. Clinical presentation of BSS includes purpura, epistaxis, menorrhagia, and mucocutaneous bleed. Laboratory diagnosis is based on prolonged bleeding time, moderate-to-severe thrombocytopenia, giant platelets, genetic test for mutations of GPIbIXV is necessary. Management varies once you recognize the cause. Platelets transfusion and antifibrinolytics are the mainstay of therapy.

Key Clinical Message
We need to be aware of rare causes of persistent thrombocytopenia as Bernard–Soulier syndrome (BSS). When BSS is suspected based on family history and giant platelets, genetic test for mutations of GPIbIXV is necessary. Management varies once you recognize the cause. Platelets transfusion and antifibrinolytics are the mainstay of therapy.

Keywords
Platelet, disorder, bleeding, thrombocytopenia, Bernard–Soulier syndrome, glycoprotein XI.
**Case Report**

Eight year old Saudi boy presented with history of gum bleeding on 19/12/2016. Other systemic review was unremarkable. He was not on any medications. On physical examination, he was conscious, not in distress. He had purpuric rash and ecchymosis lesions in lower limb. No lymphadenopathy is noted. His abdomen was not distended, and his spleen and liver were not palpable. Other systemic examinations were unremarkable. Laboratory findings were: complete blood count showed hemoglobin of 11.7 g/dL (12.0–14.0 g/dL), white blood cell 6.3 \( \times \) 10\(^9\)/L (4.0–12.0 \( \times \) 10\(^9\)/L), absolute neutrophilic count 2.5, and platelets were only 20 \( \times \) 10\(^9\)/L (150–450 \( \times \) 10\(^9\)/L).

The remaining of hematological result was within normal limits. Blood smear showed decreased number as well as large and giant platelets as showed in Figure 1. The patient was managed as a case of Idiopathic Thrombocytopenia Purpura (ITP) and received Intravenous immunoglobulin (IVIG) with no response. He responded to platelet transfusion as the platelet count increased to 56 \( \times \) 10\(^9\)/L (150–450 \( \times \) 10\(^9\)/L). As this finding was highly suggestive of BSS, we arranged a follow-up appointment and sent for genes analysis of BSS.

The result of molecular genetic analysis of the genes GP1BA, GP1BB, and GPIX showed a presence of a homozygous nucleotide substitution (TTT-TCT) leading to the change in Phe71Ser in GPIX. Finally, he was diagnosed with BSS and treated with platelet transfusion with improvement.

**Methodology**

Genomic DNA extraction and capture of the gene region of GP1BA, GP1BB, and GPIX using a DNA extraction kit (Trusight one kit, Illumina) and high throughput sequencing on NextSeq sequencer.

The molecular analysis identified homozygous mutation in the GPIX gene. This is a rare variant in well-conserved region of the protein which causes the substitution of a nonpolar and aromatic phenylalanine with a polar and aliphatic serine. This mutation previously classified as pathogenic in ClinVar and HGMD (Human Gene Mutation Database). This mutation may lead to production of an altered GPIX subunit that is broken down early or that cannot get to the platelet surface. Lack of this subunit on the surface of platelets prevents formation of the GPIb-IX-V complex and leads to the related bleeding disorder. Therefore, this mutation is likely the cause of the symptoms of the patient (Table 1).

**Discussion**

BSS is a rare inherited platelet disorder that was first reported in 1948 by Jean Bernard and Jean-Pierre Soulier as a case of a young male patient with prolonged bleeding time and thrombocytopenia with large giant platelets that is caused by abnormal function of the platelet Gp Ib-IX-V receptor complex [5].

More than 100 cases of BSS cases have been reported in the literature with 1:1 ratio of female-to-male affection [6].

Until now, 47 genetic defects have been associated with BSS and the largest number of mutations in GPIBA (20 mutations) followed by 16 mutations in GPIBB and 11 mutations in GPIX. These genetic defects could be divided into three categories: a missense mutation that can result into a decrease expression of single abnormal receptor or most likely to an unstable complex, nonsense mutation that leads to smaller subunits that lack the transmembrane region, frameshift insertions or deletions resulting in a new polypeptide [7].

In our patient, the gene analysis revealed a point mutation in the codon 71 of the GPIX gene which leads to the substitution of a phenylalanine to a serine that was observed in all clones with no other mutations detected in the GPIba and GPIbb genes. These results suggest that the mutation reported here can be the genetic cause that is responsible for the BSS phenotype.

All the genetic mutations of GPIX that have been previously reported are arranged in (Table 2).

In this case, we identified a homozygous mutation within the GPIX gene. A substitution of phenylalanine to serine at position 71 leads to the production of abnormal GPIX subunit. The absence of this subunit expression on the surface of the platelet prevents the formation of GPIb-IX-V complex that is necessary for binding of Von
Willebrand Factor to platelets resulting in bleeding tendency that is observed clinically.

**Conclusions**

Bernard–Soulier syndrome is a rare inherited platelet-bleeding disorder that is characterized by episodes of recurrent bleeding. Laboratory features in BSS show prolonged bleeding time and thrombocytopenia with large giant platelets. This disease is transmitted in autosomal recessive manner. Up to date, eleven mutations in form of amino acid substitution of GPIb in patients with BSS have been reported. We identified a homozygosity point mutation in the GPIb gene of patient with BSS that caused a substitution (TTT-TCT) of a phenylalanine 71 to serine. This nucleotide substitution caused an absence of GPIb expression on the platelet's membrane. In our case, the dysfunction of GPIb–IX complex is caused by this mutation resulting in clear diagnosis of this patient with BSS.

We need to be aware of rare causes of persistent thrombocytopenia as BSS. When BSS is suspected based on family history and giant platelets on peripheral smear, genetic test for mutations of GPIbIXV is necessary. Management varies once you recognize the cause. Platelets transfusion and antifibrinolytics are the mainstay of therapy in our patient.

**Authorship**

SI, AG, DS, and BB: wrote the manuscript and reviewed it with the literature review. HI: Main author, supervised, corrected, and reviewed the manuscript and provided direct care to the patient. All authors: read and approved the final manuscript.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**References**

1. Kunishima, S., T. Yamada, M. Hamaguchi, et al. 2006. Bernard-Soulier syndrome due to GPIb W127X mutation in Japan is frequently misdiagnosed as idiopathic thrombocytopenic purpura. Int. J. Hematol. 83:366–367.
2. Hadjkacem, B., I. Ben Amor, M. Smaoui, et al. 2010. Bernard Soulier Syndrome: a rare bleeding disorder with a wide range of genetic defects. J. Coagul. Disord. 2.
3. Mhawech, P., and A. Saleem. 2000. Inherited giant platelet disorders classification and literature review. Am. J. Clin. Pathol. 113:176–190.
4. Savoia, A., S. Kunishima, D. De Rocco, et al. 2014. Spectrum of the mutations in Bernard–Soulier syndrome. Hum. Mutat. 35:1033–1045.
5. Pham, A., and J. Wang. 2007. Bernard-Soulier syndrome: an inherited platelet disorder. Arch. Pathol. Lab. Med. 131:1834–1836.
6. Hadjkacem, B., J. Gargouri, and A. Gargour. 2011. Bernard Soulier Syndrome: a genetic bleeding disorder. Adv. Study Genet. Disord. https://doi.org/10.5772/23342.
7. Lanza, F. 2006. Bernard-Soulier syndrome (Hemorrhagiparous thrombocytic dystrophy). Orphanet J. Rare Dis. 1:46.
8. Wright, S., K. Michaelides, D. Johnson, N. West, and E. Tuddenham. 1993. Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood 81:2339–2347.
9. Clemetson, J., P. Kyrle, B. Brenner, and K. Clemetson. 1994. Variant Bernard-Soulier syndrome associated with a homozygous mutation in the leucine-rich domain of glycoprotein IX. Blood 84:1124–1131.
10. Lanza, F., C. De La Salle, M.-J. Baas, A. Schwartz, B. Boval, J.-P. Cazenave, et al. 2002. A Leu7Pro mutation in the signal peptide of platelet glycoprotein (GP) IX in a case of Bernard-Soulier syndrome abolishes surface expression of the GPIb–V–IX complex. Br. J. Haematol. 118:260–266.
11. Rivera, C. E., J. Villagra, M. Riordan, S. Williams, K. J. Lindstrom, and M. E. Rick. 2001. Identification of a new mutation in platelet glycoprotein IX (GPIX) in a patient with Bernard-Soulier syndrome. Br. J. Haematol. 112:105–108.
12. Noris, P., E. Arbustini, P. Spedini, S. Belletti, and C. L. Balduini. 1998. A new variant of Bernard-Soulier syndrome characterized by dysfunctional glycoprotein (GP) Ib and severely reduced amounts of GPIX and GPV. Br. J. Haematol. 103:1004–1013.
13. Noris, P., S. Simsek, J. Stibbe, and A. E. G. K. Von Dem Borne. 1997. A phenylalanine-55 to serine amino-acid substitution in the human glycoprotein IX leucine-rich repeat is associated with Bernard-Soulier syndrome. Br. J. Haematol. 97:312–320.
14. Suzuki, K., T. Hayashi, A. Yahagi, J. Akiba, K. Tajima, S. Satoh, et al. 1997. Novel point mutation in the leucine-rich motif of the platelet glycoprotein IX associated with Bernard-Soulier syndrome. Br. J. Haematol. 99:794–800.
15. Noda, M., K. Fujimura, T. Takafula, et al. 1996. A point mutation in glycoprotein IX coding sequence (Cys73[TGT] to Tyr[TAT]) causes impaired surface expression of GPIb/IX/V complex in two families with Bernard-Soulier syndrome. Thromb. Haemost. 73:874–878.
16. Kunishima, S., Y. Tomiyama, S. Honda, Y. Kurata, T. Kamiya, K. Ozawa, et al. 1999. Cys97→Tyr mutation in the glycoprotein IX gene associated with Bernard-Soulier syndrome. Br. J. Haematol. 107:539–545.
17. Noda, M., K. Fujimura, T. Takafula, et al. 1995. Heterogeneous expression of glycoprotein Ib, IX and V in platelets from two patients with Bernard-Soulier syndrome caused by different genetic abnormalities. Thromb. Haemost. 74:1411–1415.
18. Garner, C., S. Best, S. Menzel, H. Rooks, T. D. Spector, and S. L. Thein. 2005. Two candidate genes for low platelet count identified in an Asian Indian kindred by genome-wide linkage analysis: glycoprotein IX and thrombopoietin. Eur. J. Hum. Genet. 14:101–108.
19. Wang, Z., X. Zhao, W. Duan, J. Fu, M. Lu, G. Wang, et al. 2004. A novel mutation in the transmembrane region of glycoprotein IX associated with Bernard-Soulier syndrome. Thromb. Haemost. 92:606–613.
20. Drouin, J., N. L. Carson, and O. Laneuville. 2005. Compound heterozygosity for a novel nine-nucleotide deletion and the Asn45Ser missense mutation in the glycoprotein IX gene in a patient with Bernard-Soulier syndrome. Am. J. Hematol. 78:41–48. https://doi.org/10.1002/ajh.20236.